Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Curetis-Opgen 2022 / Zal het dan dit jaar wat worden ?
Volgen
DAGEVOS schreef op 27 mei 2022 11:06 :
Ik geloof er nog steeds in. Gisteren mooie koerssprong op het bericht dat een test 39 behandeluren kan winnen. Gezondheidszorginstellingen zullen gedwongen worden om dit soort testen te gaan gebruiken als er nog meer geldschaarste komt. Kwestie van tijd. Een RS ligt in het verschiet, maar hoeft niet perse nadelig te zijn.
Ook de verkoop van een onderdeel aan China kan flink geld in het laatje brengen.
Verder beetje gebruikmaken op grillige koersbewegingen. Volgens mij ligt de waarde van het aandeel rond de 30 cent.
Reële Kaspositie/ koers. Gemiddelde aankoop 0,84ct. Nog een lange weg te gaan. Volgend jaar verwacht ik de eerste echte tekenen van groei.
Vergeet dit rampenfonds maar gauw, want dit wordt niks meer. Een de volgende RS zal de koersval versnellen, want er komen dan weer miljoenen nieuwe aandelen bij.
DAGEVOS schreef op 27 mei 2022 11:06 :
Ook de verkoop van een onderdeel aan China kan flink geld in het laatje brengen.
Heb je hier een bron / link van ?
kijk eens op yahoo OPGN forum conversations
Volg ik. Heb ik behalve een hoop onzin nooit iets gezien van een verkoop van activiteiten aan een chinese partij. Wel iets van een nog steeds hangende chinese goedkeuring waar weer een afnamecontract van af hangt, maar dat is niet wat jij beschrijft. Als je toch wil proberen de koers op te krikken, doe dat dan met feiten en niet met iets op yahoo conversations. Straks ga je nog naar stocktwits verwijzen voor 'nieuws' en 'advies'
"Once NMPA approves the products, BCB has agreed to contractual minimum purchases of 360 Unyvero systems and more than 1.5 million cartridges cumulative over an 8-year exclusivity period which at current transfer prices between the parties is expected to amount to approximately $180 million in revenue to OpGen at current exchange rates."ir.opgen.com/news-releases/news-relea... Voor de volledigheid : "announced today that it has recently received regulatory approval of the Curetis Unyvero System as an in vitro diagnostics (IVD) instrument system in China from the Chinese authorities" Maar : "Once we also receive NMPA approval for the Unyvero pneumonia cartridge for the Chinese market we expect a swift commercial launch in China by our partners BCB " Het apparaat is dus al goedgekeurd, maar de cartridges voor de tests nog niet.
Pitmans schreef op 28 mei 2022 16:23 :
"Once NMPA approves the products, BCB has agreed to contractual minimum purchases of 360 Unyvero systems and more than 1.5 million cartridges cumulative over an 8-year exclusivity period which at current transfer prices between the parties is expected to amount to approximately $180 million in revenue to OpGen at current exchange rates."
ir.opgen.com/news-releases/news-relea... Voor de volledigheid : "announced today that it has recently received regulatory approval of the Curetis Unyvero System as an in vitro diagnostics (IVD) instrument system in China from the Chinese authorities"
Maar : "Once we also receive NMPA approval for the Unyvero pneumonia cartridge for the Chinese market we expect a swift commercial launch in China by our partners BCB "
Het apparaat is dus al goedgekeurd, maar de cartridges voor de tests nog niet.
Gewoonlijk komt er niks terecht van Chinese deals.
Met de koers gaat het anders wel goed. Van 0,32 naar 0,68dollarcent
wat zeg ik 77ct al op het bord geweest
Ik heb er 1500 x op 70 dollar cent wat a adviseren jullie?
Ik hou ze voorlopig nog vast. Het kan zo maar zijn dat hij boven de dollar noteert binnenkort. Opgn is altijd verrassend, zowel naar beneden als naar boven. Als je het geld niet direct nodig hebt dan laten staan tot bv eind van het jaar. Er komen best wel positieve berichten het komend half jaar. Is mijn verwachting.
Mooie order van 1 miljoen uit Qatar binnen.
H1 omzet $1,4mio. Deze CEO is duidelijk zijn jaarsalaris van $400k+ waard. OpGen Reports Second Quarter 2022 Financial Results and Provides Business Update Thu, August 11, 2022 at 10:15 PM Total Q2 2022 revenues of $1.0 million with product sales a key growth driver First two commercial customer contracts for Acuitas AMR Gene Panel signed in June and July 2022 Requested additional 180-day period to regain compliance with Nasdaq minimum bid price rule Management conference call scheduled for August 11th, 2022, at 4:30 p.m. EDT ROCKVILLE, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter 2022 financial and operating results. Management will host an investor call to discuss quarterly results and provide a business update. Oliver Schacht, President & CEO of OpGen, commented, “We are pleased with the progress we’ve made in the first half of 2022, which includes signing two commercial contracts for our Acuitas AMR Gene Panel with two major U.S. hospitals. Additionally, we have added a fourth trial site and continued enrollment towards our 1,500th patient sample for the clinical trial for Unyvero Urinary Tract Infection (UTI) Panel. We anticipate completing the enrollment and expect final data read out in the second half of this year towards an FDA submission.” Dr. Schacht continued, “Overall we are tracking well against our R&D milestones and continue to progress on the commercial front with significant growth in direct product sales year over year. We look forward to continuing to update on our progress and continue the fight against antimicrobial resistance.” Second Quarter and First Half 2022 Financial Results of OpGen, Inc. Total revenue for the second quarter of 2022 was approximately $1.0 million, compared with approximately $0.8 million in the second quarter of 2021. Total revenue for the first half of 2022 was approximately $1.4 million, as compared to approximately $1.6 million for the first half of 2021. Operating expenses for the second quarter of 2022 were approximately $6.2 million, compared with approximately $7.0 million in the second quarter of 2021. Operating expenses for the first half of 2022 were approximately $12.6 million, compared with approximately $14.0 million in the first half of 2021. The net loss available to common stockholders for the second quarter of 2022 was approximately $5.8 million, or $0.13 per share, compared with approximately $7.1 million, or $0.19 per share, in the second quarter of 2021. The net loss available to common stockholders for the first half of 2022 was approximately $12.6 million, or $0.27 per share, compared with approximately $21.9 million, or $0.65 per share, in the first half of 2021. Cash and cash equivalents were approximately $16.6 million as of June 30, 2022, compared with $36.1 million as of December 31, 2021.
In the reporting quarter and year to date, the Company reached the following key milestones: OpGen signed its first two commercial customer contracts for the Acuitas AMR Gene Panel in June and July 2022 with a major 1,000+ bed teaching hospital in the Northeast and a renowned 400+ bed children’s hospital in the Midwest OpGen subsidiary Ares Genetics extended its collaboration agreement with Sandoz until 2025, to drive cutting-edge digital solutions in the global fight against antimicrobial resistance (AMR) OpGen subsidiary Ares Genetics also commercially launched new sequencing and analysis services globally, which includes ARESid and ARESiss Express OpGen announced interim analysis results from its clinical trial for Unyvero UTI Panel and added a fourth trial site OpGen to date has enrolled over 1,300 patient samples in the clinical trial for Unyvero UTI Panel and is on track towards the enrollment goal of 1,500 prospective patient samples OpGen subsidiary Curetis and Leader Life Sciences entered into a Unyvero distribution partnership within the United Arab Emirates and Qatar for a total value of approximately $1 million in revenue during the initial three-year term OpGen subsidiary Curetis and Keis Group entered into a three-year exclusive Unyvero distribution partnership in Kosovo based on Keis’ successfully won tender for Unyvero products OpGen and Menarini expanded their distribution agreement to increase the annual minimum revenue commitment by Menarini in the next two years, in addition to the sale of around 70 installed Unyvero systems across nine European countries at residual fair market value from OpGen’s subsidiary Curetis to Menarini OpGen announced publication of results from a major prospective, multi center, randomized and interventional clinical study using Unyvero Hospitalized Pneumonia (HPN) Panel in The Lancet Respiratory Medicine that demonstrated Unyvero decreases the duration of inappropriate antibiotic therapy in hospitalized patients with pneumonia OpGen announced publication of results of Unyvero HPN Panel for detection of bacterial respiratory tract pathogens from serial specimens collected from hospitalized COVID-19 patients at Karolinska University Hospital (Sweden), confirming the ability of Unyvero in detecting potential pneumonia pathogens earlier than culture OpGen commenced a new At The Market (ATM) sales facility for up to approximately $10.7 million, pursuant to which the Company may sell, from time to time, in an “at the market” offering shares of its common stock. While no shares were sold under this new ATM in H1 2022, in July and August to date the Company has sold approximately 1.7 million new shares of its common stock for gross proceeds of approximately $1 million. OpGen requested an additional 180-day period from Nasdaq to regain compliance with the $1.00 minimum bid price rule and expects their decision by the end of August. In terms of fiscal 2022 guidance, OpGen expects: U.S. direct product sales of Unyvero and Acuitas are anticipated to contribute to growth Continuous increase in its European and international distribution business for Unyvero products Expand Ares Genetics strategic collaborations and partnerships and launch U.S. Next Generation Sequencing lab services in Q3 2022 Overall, 2022 revenue growth of approximately 25% year over year from the products and services business globally Conference Call Information OpGen’s management will host a conference call today, August 11th at 4:30 p.m. EDT, to go over the second quarter and first half of 2022 financial results and business activities, as well as answer analyst questions.
Zoals verwacht blijft het kommer en kwel bij Opgen. Dit wordt nooit meer wat.
cashburn H1 bijna $20mio. Met een cashvoorraad van $16.6mio wordt einde jaar dus niet gehaald. Maar dar is al een oplossing voor : er is alweer een nieuwe emissie van $10.7mio uitgezet, waarvan $1mio al is opgehaald door verkoop van 1.7mio stukken. In dit tempo komen er dus nog eens 18mio stukken bij. Maar dat is alleen maar gunstig, want zolang je verlies maakt, wordt het verlies per aandeel dus kleiner ;o)
Soort van goed nieuws. Dus daalt de koers ;o) Nasdaq Grants OpGen 180-Day Extension to Meet Minimum Bid Price Requirement OPGN -3.22% OpGen, Inc. Wed, August 31, 2022 at 1:30 PM ROCKVILLE, Md., Aug. 31, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that it has received written notification from the Listing Qualification Department of The NASDAQ Stock Market ("Nasdaq") granting OpGen’s request for a 180-day extension to regain compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). OpGen now has until February 27, 2023 to regain compliance with the Bid Price Rule. Nasdaq's extension notice has no immediate effect on the continued listing status of OpGen’s common stock, which remains listed on The NASDAQ Capital Market. If at any time until February 27, 2023, the bid price for OpGen’s common stock closes at or above $1.00 per share for a minimum of ten consecutive trading days, OpGen will regain compliance with the Bid Price Rule. OpGen will continue to monitor the bid price for its common stock and consider various available options if OpGen’s common stock does not trade at a level that is likely to regain compliance with the Bid Price Rule. There can be no assurance that OpGen will regain compliance with the Bid Price Rule or maintain compliance with any of the other Nasdaq continued listing requirements during this extended compliance period.
Tjonge, tjonge en vooral tjonge. Wat sneller dan verwacht, maar gezien de koersontwikkeling van de laatste weken niet helemaal onverwacht, is vandaag de ATL wat scherper gesteld naar $0,30 . Reden : een nieuwe sloot aandelen erbij tegen een prijs die de $1-regel van nasdaq wel heel ver uit beeld brengt plus de aankondiging dat de RSS aan de aandeelhouders wordt voorgelegd. Plus dat de strike price van warrants van eerdere financieringsrondes, die nu toch wel erg ongunstig is geworden, gewoon wordt verlaagd naar $0,377 (was $2,05 tot zelfs $ 65). Zo gaat dat in beleggersland. Maar het zal ooit toch allemaal nog wel goed komen ? --------------------------- OpGen Announces $3.38 Million Registered Direct Offering OPGN -17.6799% - OpGen, Inc. Fri, September 30, 2022 at 2:38 PM ROCKVILLE, Md., Sept. 30, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale in a registered direct offering of 9,660,000 shares of the Company’s common stock (or common stock equivalents), 33,810 shares of Series C mirroring preferred stock (“Series C Preferred”) and, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 9,660,000 shares of common stock, at a purchase price of $0.35 per share (or common stock equivalent). Each share of Series C Preferred Stock has a stated value of $0.01 per share and will automatically terminate on the date that the Company effects a reverse stock split of the Company’s shares of common stock. The warrants have an exercise price of $0.377 per share, will become exercisable six months following the date of issuance and will expire five and one-half years following the date of issuance. The closing of the offering is expected to occur on or about October 3, 2022, subject to the satisfaction of customary closing conditions. (...) The Company expects to call a special meeting of stockholders for the approval of a proposal to effect a reverse stock split of the Company’s common stock (the “Proposal”). (...) The Company also has agreed that certain existing warrants to purchase up to an aggregate of 14,829,751 shares of common stock of the Company that were previously issued to the investor, with exercise prices ranging from $2.05 to $65.00 per share and expiration dates ranging from February 2023 to April 2027, will be amended effective upon the closing of the registered direct offering so that the amended warrants will have a reduced exercise price of $0.377 per share, will not be exercisable until six months following the closing of the registered direct offering and will expire five and one-half years following the closing of the registered direct offering."finance.yahoo.com/news/opgen-announce...
Nee, het komt nooit meer goed met dit rampen-aandeel. Alles gaat precies zoals ik ca 2 jaar geleden heb voorspeld.
DeZwarteRidder schreef op 27 mei 2022 11:48 :
[...]Vergeet dit rampenfonds maar gauw, want dit wordt niks meer.
Een de volgende RS zal de koersval versnellen, want er komen dan weer miljoenen nieuwe aandelen bij.
En inderdaad........!!!
ATL nog een stuk scherper gezet op $0,2695 uiteindelijk. Maar nabeurs weer gesloten boven 30 cent, er is dus niks aan de hand.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee